



Atty. Dkt. No. 053466/0234

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Masayuki TSUCHIYA, et al.**

RECEIVED

Title: **Reshaped Human Antibody To Human Interleukin-6 Receptor**

JUN 25 2002

Appl. No.: **09/114,285**

TECH CENTER 1600/2900

Filing Date: **July 13, 1998**

Examiner: **G. Bansal**

Art Unit: **1642**

AMENDMENT AND REPLY UNDER 37 C.F.R. §1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the Office Action dated April 17, 2002, the due date for response having been extended one month to Sunday, June 16, 2002, Applicants submit the following Amendment and Reply under 37 C.F.R. § 1.111.

Applicants concurrently file herewith a Petition for Extension of Time under 37 C.F.R. § 1.136(a), with provision for the required fee, to extend the period for response for one month up to, and including, Sunday, June 16, 2002. If additional fees are necessary to prevent abandonment of this application, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741.

IN THE SPECIFICATION:

Please amend the specification as follows:

On page 22, delete the first full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

Once the starting plasmid DNAs containing the desired human FRs were selected, PCR primers were designed to enable the substitution of the mouse PM-1 CDRs in place of the mouse D1.3 CDRs. For each reshaped human PM-1 V region, three primers containing the DNA sequences coding for the mouse PM-1 CDRs and two primers flanking the entire DNA sequence coding for the reshaped human V region were designated and synthesized. Using the five PCR primers in a series